Promising results from Phase II clinical trial

American association cancer research We were encouraged to see some very promising results from a Phase II clinical trial for high grade Neuroendocrine Carcinoma (NEC) patients, using a combination of Immunotherapy drugs. The results of this trial were recently presented at the American Association for Cancer Research Annual Meeting.

Click here for link to full press release

We welcome more research for these NEC patients and all NET Cancer patients and look forward to seeing more results based on real world experience.

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

$3 million boost for neuroendocrine cancer research: PLANETARI launches nationally

Read article

NECA Joins Boehringer Ingelheim Panel Discussion on Clinical Trials and Patient Access

Read article

Expressions of interest open for ANZSNM nurse and allied health workshop in Canberra

Read article

NECA partners with Oncidium ahead of World Radiotheranostics Day 2026

Read article

Quick Links

Newly Diagnosed
Living with NETs
Optimal Care Pathway
Close

Neuroendocrine Cancer Day

Neuroendocrine Cancer Day is on 10 November, and every bit of support counts.

Create an event, share your artwork, or donate on our ‘Double Your Impact’ days. There are so many ways to stand with the NET community.

Get Involved